Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Parallel-group, Open-labelled, Multinational Trial Comparing the Efficacy and Safety of Insulin Detemir (Levemir) Versus Human Insulin (NPH Insulin), Used in Combination With Insulin Aspart as Bolus Insulin, in the Treatment of Pregnant Women With Type 1 Diabetes.

Next Previous
Trial Profile

A Randomised, Parallel-group, Open-labelled, Multinational Trial Comparing the Efficacy and Safety of Insulin Detemir (Levemir) Versus Human Insulin (NPH Insulin), Used in Combination With Insulin Aspart as Bolus Insulin, in the Treatment of Pregnant Women With Type 1 Diabetes.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin detemir (Primary) ; Insulin suspension isophane
  • Indications Gestational diabetes; Type 1 diabetes mellitus
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 25 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Jun 2010 Trial design and rationale have been presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA 2010).
    • 06 Apr 2010 Planned end date changed from Oct 2010 to Aug 2010 as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top